经肠饲管给予艾沙康唑胶囊在移植受者中可达临床血药浓度
BACKGROUND: Isavuconazole is a triazole antifungal available in IV and capsule formulation. Prescribing information states that capsules should not be chewed, crushed, dissolved or opened because the drug was not studied in this manner.…
要点
- 经肠饲管给予艾沙康唑胶囊可达临床有效血药浓度。
- 中位血药浓度为1.8 μg/mL,范围0.3-5.2 μg/mL。
- 既往是否静脉给药对浓度无显著影响(P=0.896)。
核心结论
- 经肠饲管给予硫酸艾沙康唑胶囊内容物用于侵袭性真菌感染的预防或治疗是合理的。
研究设计与样本
- 纳入标准为经肠饲管给药至少5天且进行了治疗药物监测。
主要发现
- 治疗药物监测在中位肠饲管给药7天(范围6-17天)后进行,总体艾沙康唑治疗中位15天(范围7-174天)。
- 中位艾沙康唑浓度为1.8 μg/mL(范围0.3-5.2)。
- 既往接受或未接受静脉给药的患者中位浓度分别为1.8 μg/mL(范围0.3-5.2)和2.2 μg/mL(范围0.8-3.6),P=0.896。
- 6例先后接受静脉和肠饲管给药并均进行监测的患者中,肠饲管途径浓度与静脉途径相似或更高。
临床怎么用
- 可考虑将硫酸艾沙康唑胶囊打开,将内容物经肠饲管给予,用于侵袭性真菌感染的预防或治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Isavuconazole is a triazole antifungal available in IV and capsule formulation. Prescribing information states that capsules should not be chewed, crushed, dissolved or opened because the drug was not studied in this manner. However, considering the pharmacokinetics of the capsules, we theorized opening and sprinkling the contents into an enteral feeding tube (EFT) would result in adequate absorption and systemic concentrations of isavuconazole. OBJECTIVES: To determine whether patients receiving isavuconazonium sulphate capsules via EFT would achieve clinical blood concentrations of isavuconazole. METHODS: Nineteen solid organ and HCT recipients receiving isavuconazole via EFT for prevention or treatment of invasive fungal infection (IFI) were prospectively identified at four academic medical centres in the USA. Patients were included in this evaluation if they received isavuconazole via EFT for at least 5 days and therapeutic drug monitoring (TDM) was performed. RESULTS: TDM was performed after a median of 7 days (range 6-17) following EFT administration and 15 days (range 7-174) of isavuconazole therapy overall. Median isavuconazole concentration was 1.8 μg/mL (range 0.3-5.2). Median isavuconazole concentrations in patients with or without prior IV administration were 1.8 μg/mL (range 0.3-5.2) and 2.2 μg/mL (range 0.8-3.6; P = 0.896), respectively. Concentrations achieved with the EFT route were similar to or greater than the corresponding concentrations via the IV route in six patients who had TDM performed during both routes of administration. CONCLUSIONS: It is reasonable to consider opening isavuconazonium sulphate capsules and administering the contents enterally for prevention and treatment of IFI.
引用
- McCreary EK, Nguyen MH, Davis MR, et al. Achievement of clinical isavuconazole blood concentrations in transplant recipients with isavuconazonium sulphate capsules administered via enteral feeding tube. J Antimicrob Chemother. 2020. PMID: 32710097. doi:10.1093/jac/dkaa274
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。